公司资料
Longeveron 股价、新闻与催化剂
- 股票代码:
- LGVN
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.84 USD (+2.02%)
收盘价
最后更新: 2026年8月21日
24M USD
市值
股价为何变动
The latest monitored company update is “Longeveron Announces 1-for-10 Reverse Stock Split.” The corresponding closing-price reaction is not yet available.
公司概览
Regenerative Medicine Company
Longeveron develops allogeneic cellular therapies for rare pediatric and chronic aging-related conditions.
Laromestrocel
Laromestrocel, formerly Lomecel-B, is manufactured from bone marrow-derived medicinal signaling cells obtained from young healthy adult donors.
Hypoplastic Left Heart Syndrome
The ELPIS program evaluates laromestrocel as an adjunct to staged surgery in infants with hypoplastic left heart syndrome, an orphan pediatric condition.
Additional Regenerative Applications
The company is also exploring laromestrocel in aging-related and neurological conditions where inflammation and impaired tissue repair may contribute to disease.
未来催化剂
- Topline results from the Phase 2b ELPIS II study in hypoplastic left heart syndrome are expected in August 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。